In comparing LCTC to BLO/BLOZF:
From Cannabix latest quarterly update:
Net loss for the period ended October 31, 2018 was $2,242,534
During the three-month period ended October 31, 2018, the Company incurred expenses of $2,277,678
The Company has not begun commercial sales of any of its technology holdings and nor has production occurred from activities on its resource properties and accordingly, the Company does not generate cash from operations. (Not one sale or source of revenue) The Company finances technology development by raising capital from equity markets. (That means constant dilution of shareholders)
If additional funds are required, the Company plans to raise additional capital primarily through the private placement of its equity securities.
As the Company does not currently generate revenue, cash balances will continue to decline as funds are utilized to conduct its operations, unless replenished by capital fundraising.
The Company’s operations to date have been financed by the issuance of its common shares. The Company continues to seek capital through various means including the issuance of equity and debt.
As of October 31, 2018 the Company had 101,632,732 common shares issued and outstanding. Plus an additional 5 million warrants outstanding, and 8,364,872 stock options outstanding
The Company expects to be involved in research and development to create several prototype marijuana breathalyzers and then performing extensive trial testing and conducting research studies with such devices prior to determining their commercial viability. This process may take several years and require significant financial resources without income. The Company expects these expenses to result in continuing operating losses for the foreseeable future.
Quarterly Net loss numbers: (2,242,534) (309,578) (477,322) (336,651) (357,394) (296,670) (1,210,131) (1,499,042)
Total loss over the last two years = $6,729,322
Market cap BLOZF = $110,779,678
Market cap LCTC = $12,638,615
BLOZF valued 8.7x
There is no way in hell that Cannabix should have a valuation over 8 times that of Lifeloc.
At absolute minimum, Lifeloc should be valued at half that of Cannabix.
That would equate to a $55 million market cap and a share price of $22.40.
I personally believe that Lifeloc will eventually see at least a valuation that is twice that of Cannabix. With human trials in the near future and progress being made with the SpinDx technology and marijuana breathalyzer I expect this to happen sooner rather than later.
Any comments are welcome!
Thanks
AI
